At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 400 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab and Placebo for Psoriatic Arthritis. Completed, enrolled 400 participants across 92 sites in 11 countries.
Detailed Summary
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR) subjects with active Psoriatic Arthritis (PsA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustralia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russia, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartMar 2019
First PostedApr 2019
Primary CompletionDec 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedApr 1, 2019
Enrollment StartMar 28, 2019
Primary CompletionDec 8, 2021
Study CompletionFeb 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.3 years ago
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.
Placeboother
Subjects will receive placebo at pre-specified time-points.